Optomed operates in two business segments: Devices and Software. The company has an extensive portfolio of over 50 international patents protecting its technology and has medical approvals in all key markets, including CE (Europe), FDA (USA), and CFDA (China). The Devices segment achieved 47.0% currency-adjusted growth in Q3 2025, with the US market performing very well.
Cyborg Score Rationale
Optomed operates in a growing healthcare sector with strong AI-integrated technology, demonstrated by recent robust growth in its Devices segment and global expansion across 60+ countries. The company's strong IP portfolio and regulatory approvals provide competitive moats, though limited scale (100 employees) and public market visibility present execution risks.
Top Insights
Strong momentum in US market with 47% currency-adjusted Devices segment growth in Q3 2025
Vertically integrated strategy combining proprietary handheld hardware with AI-powered software for screening
Global reach across 60+ countries positions company to benefit from increasing prevalence of diabetic retinopathy
Robust IP protection with 50+ international patents and regulatory approvals across major markets (CE, FDA, CFDA)